Resistance to EGFR-Targeted Therapy: A Family Affair

Gregory Vlacich, Robert J. Coffey

Research output: Contribution to journalShort survey

40 Scopus citations

Abstract

The EGFR-directed antibody cetuximab has proven, albeit modest, clinical benefit as monotherapy in head and neck and colorectal cancers. In a recent study, Yonesaka et al. uncovered a new mechanism of cetuximab resistance mediated by increased ERBB2 signaling via amplification of ERBB2 or increased levels of the ERBB3/ERBB4 ligand heregulin.

Original languageEnglish
Pages (from-to)423-425
Number of pages3
JournalCancer Cell
Volume20
Issue number4
DOIs
StatePublished - Oct 18 2011
Externally publishedYes

Fingerprint Dive into the research topics of 'Resistance to EGFR-Targeted Therapy: A Family Affair'. Together they form a unique fingerprint.

  • Cite this